Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

526 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Process of diffusing cancer survivorship care into oncology practice.
Tessaro I, Campbell MK, Golden S, Gellin M, McCabe M, Syrjala K, Ganz PA, Jacobs L, Baker S, Miller KD, Rosenstein DL. Tessaro I, et al. Among authors: miller kd. Transl Behav Med. 2013 Jun;3(2):142-8. doi: 10.1007/s13142-012-0145-4. Transl Behav Med. 2013. PMID: 24073165 Free PMC article.
ZNFX1 functions as a master regulator of epigenetically induced pathogen mimicry and inflammasome signaling in cancer.
Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Abbasi Farid E, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G, Marker R, Gohari Z, Inayatullah MMA, Tiwari VK, Kader T, Santagata S, Drapkin R, Kommoss S, Pfisterer J, Konecny GE, Coopergard R, Issa JJ, Winterhoff BJN, Topper MJ, Sandusky GE, Miller KD, Baylin SB, Nephew KP, Rassool FV. Stojanovic L, et al. Among authors: miller kd. Cancer Res. 2025 Jan 13. doi: 10.1158/0008-5472.CAN-24-1286. Online ahead of print. Cancer Res. 2025. PMID: 39804147
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller KD, Kao S, Kongpachith S, Tribouley C, Graham M, Stoll B, Patel M, Sahtout M, Blaney M, Leibman R, Golan T, Tolcher A. Shimizu T, et al. Among authors: miller kd. Front Oncol. 2024 Oct 29;14:1376551. doi: 10.3389/fonc.2024.1376551. eCollection 2024. Front Oncol. 2024. PMID: 39534099 Free PMC article.
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer.
Stojanovic L, Abbotts R, Tripathi K, Coon CM, Rajendran S, Farid EA, Hostetter G, Guarnieri JW, Wallace DC, Liu S, Wan J, Calendo G, Marker R, Gohari Z, Inayatullah MMA, Tiwari VK, Kader T, Santagata S, Drapkin R, Kommoss S, Pfisterer J, Konecny GE, Coopergard R, Issa JP, Winterhoff BJN, Topper MJ, Sandusky GE, Miller KD, Baylin SB, Nephew KP, Rassool FV. Stojanovic L, et al. Among authors: miller kd. bioRxiv [Preprint]. 2024 Oct 21:2024.10.18.618659. doi: 10.1101/2024.10.18.618659. bioRxiv. 2024. PMID: 39484607 Free PMC article. Preprint.
Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer.
Mosher CE, Lee S, Addington EL, Park S, Lewson AB, Snyder S, Hirsh AT, Bricker JB, Miller KD, Ballinger TJ, Schneider BP, Storniolo AM, Newton EV, Champion VL, Johns SA. Mosher CE, et al. Among authors: miller kd. J Clin Oncol. 2024 Oct 25:JCO2400965. doi: 10.1200/JCO.24.00965. Online ahead of print. J Clin Oncol. 2024. PMID: 39454125
526 results